title: Mesoporous persistent nanophosphors for in vivo optical bioimaging and drug-delivery.
abstract: Based upon the ambitious idea that one single particle could serve multiple purposes at the same time, the combination and simultaneous use of imaging and therapeutics has lately arisen as one of the most promising prospects among nanotechnologies directed toward biomedical applications. Intended for both therapeutics and diagnostics in vivo, highly complex nanostructures were specifically designed to simultaneously act as optical imaging probes and delivery vehicles. Yet, such multifunctional photonic nanoplatforms usually exploit fluorescence phenomena which require constant excitation light through biological tissues and thus significantly reduce the detection sensitivity due to the autofluorescence from living animals. In order to overcome this critical issue, the present article introduces a novel multifunctional agent based on persistent luminescence mesoporous nanoparticles. Being composed of a hybrid chromium-doped zinc gallate core/mesoporous silica shell architecture, we show that this nanotechnology can be used as an efficient doxorubicin-delivery vehicle presenting a higher cytotoxicity toward U87MG cells than its unloaded counterpart in vitro. In addition, we demonstrate that a persistent luminescence signal from these doxorubicin-loaded mesoporous nanophosphors opens a new way to highly sensitive detection in vivo, giving access to the real-time biodistribution of the carrier without any autofluorescence from the animal tissues. This new persistent luminescence-based hybrid nanotechnology can be easily applied to the delivery of any therapeutic agent, thus constituting a versatile and sensitive optical nanotool dedicated to both therapeutic and diagnostic applications in vivo.
authors.affiliation: Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR 8258, INSERM U 1022, Paris, F-75270 cedex France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Maldiney
authors.forename: Benoit
authors.initials: B
authors.lastname: Ballet
authors.forename: Michel
authors.initials: M
authors.lastname: Bessodes
authors.forename: Daniel
authors.initials: D
authors.lastname: Scherman
authors.forename: Cyrille
authors.initials: C
authors.lastname: Richard
mesh_terms: D000818:Animals; D017610:Calcium Compounds / Q000737:chemistry* / Q000493:pharmacokinetics; D002857:Chromium / Q000737:chemistry* / Q000493:pharmacokinetics; D020099:Coated Materials, Biocompatible / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods; D004354:Drug Screening Assays, Antitumor; D005707:Gallic Acid / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D008163:Luminescent Measurements / Q000295:instrumentation / Q000379:methods; D051379:Mice; D054118:Nanospheres / Q000737:chemistry*; D061848:Optical Imaging / Q000295:instrumentation / Q000379:methods; D017640:Silicates / Q000737:chemistry* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D017967:Zinc Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics
chemical_list: D017610:Calcium Compounds; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D017640:Silicates; D017967:Zinc Compounds; D002857:Chromium; D005707:Gallic Acid; D004317:Doxorubicin; C031293:calcium silicate